This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Edwards Lifesciences Is Getting Healthier

Despite these results, I'm hearing about how Edwards is "struggling to meet expectations." Let's recall that its growth in the U.S. is jumping 9.6% year over year. What's more, in overseas markets like Europe, Edward posted 14% revenue growth, culminating in an 11% year-over-year jump in international sales. I'm not sure what else the company could have done.

If Boston Scientific (BSX) and Covidien (COV) are still applying pressure on Edwards transcatheter valves business, this certainly wasn't reflected in the fourth-quarter earnings. Transcatheter valve revenue was up 22%.

Equally impressive was the 5% growth the company showed outside of the transcathether business. There were complaints that the company was not as diversified as it should be. But the 5% increase, which came in higher than expected, shows the company is making progress.

In terms of operations, Edwards posted full-year adjusted earnings of $3.44 per share, which soared more than 38% year over year, beating Street estimates by a meaningful margin.

You can argue that the share count reduction contributed to this. But that's also been the case for several med-tech players. Not many have been criticized to the extent of Edwards.

It still seems some are unwilling to accept that they were wrong about the November quarter. I won't deny that Edwards still has room for improvement. For instance, revenue is the Sapien business has flat-lined. The company has been unable to meet its own guidance in that area.

But given the strength of the transcatheter side and seeing how well the company is performing both in the U.S. and internationally, I'm willing to look beyond this deficit. To do anything but appreciate the progress this company is making is to nitpick.

All told, I still like this stock. It remains to be seen if shares will recover to its 52-week high of $90, but it doesn't have to get there. With the stock trading at around $70, $80 to $82a share is an attainable goal on the basis of domestic and international market share growth.

At the time of publication the author had no position in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
EW $130.46 1.50%
TSLA $247.43 -0.01%
YHOO $43.39 1.30%
AAPL $132.03 1.90%
FB $80.55 1.50%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs